 | • レポートコード：MRC2204A080 • 出版社/出版日：Transparency Market Research / 2022年1月 • レポート形態：英文、PDF、196ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界の勃起不全（ED）治療薬市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、医薬品別（バイアグラ、シアリス、スタキシン/レビトラ、ステンドラ/スペドラ、その他）分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・世界の勃起不全（ED）治療薬市場規模：医薬品別（バイアグラ、シアリス、スタキシン/レビトラ、ステンドラ/スペドラ、その他） ・世界の勃起不全（ED）治療薬市場規模：流通チャネル別 ・世界の勃起不全（ED）治療薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Erectile Dysfunction (ED) Drugs Market – Scope of Report
TMR’s report on the global erectile dysfunction (ED) drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global erectile dysfunction (ED) drugs market for the period 2020–2028, considering 2020 as the base year and 2021 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global erectile dysfunction (ED) drugs market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global erectile dysfunction (ED) drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global erectile dysfunction (ED) drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global erectile dysfunction (ED) drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global erectile dysfunction (ED) drugs market.
The report delves into the competition landscape of the global erectile dysfunction (ED) drugs market. Key players operating in the global erectile dysfunction (ED) drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global erectile dysfunction (ED) drugs market that have been profiled in this report.
Key Questions Answered in Erectile Dysfunction (ED) Drugs Market Report
What is the scope of growth of product companies in the global erectile dysfunction (ED) drugs market?
What will be the Y-o-Y growth of the global erectile dysfunction (ED) drugs market between 2020 and 2028?
What is the influence of changing trends in technologies on the global erectile dysfunction (ED) drugs market?
Will North America be the most profitable market for medical device technology providers?
Which factors are anticipated to hamper the growth of the global erectile dysfunction (ED) drugs market during the forecast period?
Which are the leading companies in the global erectile dysfunction (ED) drugs market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global erectile dysfunction (ED) drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global erectile dysfunction (ED) drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the erectile dysfunction (ED) drugs market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the erectile dysfunction (ED) drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global erectile dysfunction (ED) drugs market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global erectile dysfunction (ED) drugs market more reliably and accurately.
レポート目次1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Secondary Research Methodology
2.2. Primary Research Methodology
2.3. Analysis Research Methodology
3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
5. Market Outlook
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Opportunity Analysis
5.1.5. Trends
5.2. Global Erectile Dysfunction Market Analysis and Forecast, 2018–2028
5.3. Porter’s Five Forces Analysis
5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
5.5. Pipeline Analysis
5.5.1. Discovery
5.5.2. Preclinical
5.5.3. IND (Investigational New Drug)
5.5.4. Phase I
5.5.5. Phase I/II
5.5.6. Phase II
5.5.7. Phase III
5.5.8. Pre-registration
5.6. Global Erectile Dysfunction (ED) Drug Market Outlook
6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Drug
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug, 2018–2028
6.3.1. Viagra
6.3.2. Cialis
6.3.3. Staxyn/Levitra
6.3.4. Stendra/Spedra
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug
7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2018–2028
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug, 2018–2028
9.2.1. Viagra
9.2.2. Cialis
9.2.3. Staxyn/Levitra
9.2.4. Stendra/Spedra
9.2.5. Others
9.3. Market Value Forecast, by Distribution Channel, 2018–2028
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2018–2028
9.4.1. U.S.
9.4.2. Canada
10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug, 2018–2028
10.2.1. Viagra
10.2.2. Cialis
10.2.3. Staxyn/Levitra
10.2.4. Stendra/Spedra
10.2.5. Others
10.3. Market Value Forecast, by Distribution Channel, 2018–2028
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2018–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug, 2018–2028
11.2.1. Viagra
11.2.2. Cialis
11.2.3. Staxyn/Levitra
11.2.4. Stendra/Spedra
11.2.5. Others
11.3. Market Value Forecast, by Distribution Channel, 2018–2028
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2018–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug, 2018–2028
12.2.1. Viagra
12.2.2. Cialis
12.2.3. Staxyn/Levitra
12.2.4. Stendra/Spedra
12.2.5. Others
12.3. Market Value Forecast, by Distribution Channel, 2018–2028
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2018–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug, 2018–2028
13.2.1. Viagra
13.2.2. Cialis
13.2.3. Staxyn/Levitra
13.2.4. Stendra/Spedra
13.2.5. Others
13.3. Market Value Forecast, by Distribution Channel, 2018–2028
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2018–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Competitive Business Strategies
14.4. Company Profiles
14.4.1. Pfizer, Inc.
14.4.1.1. Company Overview (HQ, Business Segments, Employee)
14.4.1.2. Product Portfolio
14.4.1.3. SWOT Analysis
14.4.1.4. Strategic Overview
14.4.2. Dong-A ST Co., Ltd.
14.4.2.1. Company Overview (HQ, Business Segments, Employee)
14.4.2.2. Product Portfolio
14.4.2.3. SWOT Analysis
14.4.2.4. Strategic Overview
14.4.3. Eli Lilly and Company
14.4.3.1. Company Overview (HQ, Business Segments, Employee)
14.4.3.2. Product Portfolio
14.4.3.3. SWOT Analysis
14.4.3.4. Strategic Overview
14.4.4. Bayer AG
14.4.4.1. Company Overview (HQ, Business Segments, Employee)
14.4.4.2. Product Portfolio
14.4.4.3. SWOT Analysis
14.4.4.4. Strategic Overview
14.4.5. VIVUS, INC.
14.4.5.1. Company Overview (HQ, Business Segments, Employee)
14.4.5.2. Product Portfolio
14.4.5.3. SWOT Analysis
14.4.5.4. Strategic Overview
14.4.6. SK chemicals
14.4.6.1. Company Overview (HQ, Business Segments, Employee)
14.4.6.2. Product Portfolio
14.4.6.3. SWOT Analysis
14.4.6.4. Strategic Overview
14.4.7. Meda Pharmaceuticals, Inc.
14.4.7.1. Company Overview (HQ, Business Segments, Employee)
14.4.7.2. Product Portfolio
14.4.7.3. SWOT Analysis
14.4.7.4. Strategic Overview
14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
14.4.8.1. Company Overview (HQ, Business Segments, Employee)
14.4.8.2. Product Portfolio
14.4.8.3. SWOT Analysis
14.4.8.4. Strategic Overview
14.4.9. Apricus Biosciences, Inc.
14.4.9.1. Company Overview (HQ, Business Segments, Employee)
14.4.9.2. Product Portfolio
14.4.9.3. SWOT Analysis
14.4.9.4. Strategic Overview
14.4.10. Teva Pharmaceutical Industries Ltd.
14.4.10.1. Company Overview (HQ, Business Segments, Employee)
14.4.10.2. Product Portfolio
14.4.10.3. SWOT Analysis
14.4.10.4. Strategic Overview
Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2018–2028
Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2018–2028
Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 09: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028
Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 19: Pfizer, Inc. Products Offered
Table 20: Pfizer, Inc. Recent Developments
Table 21: Dong-A ST Co., Ltd. Products Offered
Table 22: Dong-A ST Co., Ltd. Recent Developments
Table 23: Eli Lilly and Company Products Offered
Table 24: Eli Lilly and Company Recent Developments
Table 25: Bayer AG Products Offered
Table 26: Bayer AG Recent Developments
Table 27: VIVUS, INC. Ltd. Products Offered
Table 28: VIVUS, INC. Recent Developments
Table 29: SK chemicals Products Offered
Table 30: SK chemicals Recent Developments
Table 31: Meda Pharmaceuticals Inc. Products Offered
Table 32: Meda Pharmaceuticals Inc. Recent Developments
Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
Table 35: Apricus Biosciences, Inc. Products Offered
Table 36: Apricus Biosciences, Inc. Recent Developments
Table 37: Teva Pharmaceutical Industries Ltd. Products Offered